Silexion says SIL204 uses native serum lipids for cellular uptake, boosts KRAS knockdown in preclinical study
SLXN•Silexion reported preclinical data showing dose-dependent mutant KRAS knockdown by SIL204 with physiological serum lipids; lipid depletion reduced silencing (P < 0.001). The results support its Phase 2/3 program in locally advanced pancreatic cancer, while in vivo pharmacokinetics and biodistribution studies are ongoing.
1. Preclinical findings
Carrier-free assays showed dose-dependent mutant KRAS knockdown with physiological serum lipids, while lipid depletion reduced silencing (P < 0.001). Adding human LDL did not increase potency versus complete serum; Silexion said the findings support systemic subcutaneous dosing in its Phase 2/3 program for locally advanced pancreatic cancer. Ongoing work includes in vivo pharmacokinetics and biodistribution studies.
